HC Wainwright & Co. Reiterates Buy on Prelude Therapeutics, Maintains $8 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 89.5%

Neg 0% Neu 89.5% Pos 0%

HC Wainwright & Co. analyst Robert Burns reiterates Prelude Therapeutics (NASDAQ:PRLD) with a Buy and maintains $8 price target.